The company named Merck KGaA’s Belen Garijo as the successor to Paul Hudson. The change follows a string of clinical setbacks ...

The sudden departure stands in contrast to other EU pharma leaders who have been given much longer transitions in recent ...

Sanofi abruptly replaced Chief Executive Officer Paul Hudson after a massive research spending boost failed to deliver rapid results, appointing its first female leader, Merck KGaA’s Belén Garijo.

Sanofi is replacing Paul Hudson as CEO, amid questions about which medicines will drive the company's growth in the future.

Sanofi’s Board of Directors announced Belén Garijo as the company’s next CEO following the move to not renew the tenure of ...

Sanofi sold its controlling stake in the drugmaker’s consumer-health unit last year, meaning it’s now entirely reliant on innovative prescription medicines.

* Projects led by collaborating researchers from the two organizations will focus on autoimmune diseases and inflammatory conditions Exploring cytokine crosstalk in type 2 inflammation, specifically ...

BRIDGEWATER, N.J., Oct. 16, 2024 /PRNewswire/ -- Sanofi announced today it will contribute $18 million to three Historically Black Medical Schools to help the institutions work to increase diversity ...

Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline Paris, May 22, 2025. Sanofi announced today that it has entered ...

Sanofi has been an active dealmaker in the artificial intelligence space, an effort intended to beef up its capabilities in drug discovery and development. Insilico Medicine is now the latest AI ...

Sanofi establishesthree-year collaboration with Stanford Medicine to accelerate immunology research Projects led by collaborating researchers from the two organizations will focus on autoimmune ...